A pilot study including 10 patients with metastatic HER2-positive breast cancer utilized PET imaging with [18F]FDG PET and [64Cu]Cu-DOTA-trastuzumab before treatment with trastuzumab emtansine. This evidence concerns the gene ERBB2 and breast cancer.